| 1 |
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al. · Journal of Clinical Oncology
Open access |
29 May 2018 |
800 |
| 2 |
MAIT cells are activated during human viral infections
Bonnie van Wilgenburg et al. · Nature Communications
Open access |
23 Jun 2016 |
532 |
| 3 |
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber et al. · Journal of Clinical Oncology
Open access |
6 Apr 2017 |
475 |
| 4 |
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth Hugh Mayer et al. · The Lancet
Open access |
Jul 2020 |
437 |
| 5 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Mark Richard Nelson, Christine Katlama, Joan Montaner et al. · AIDS
|
Jun 2007 |
353 |
| 6 |
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study
Thomas Berg, Karl‐Georg Simon, Stefan Mauss et al. · Journal of Hepatology
|
20 Jul 2017 |
320 |
| 7 |
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Colleen Frances Kelley et al. · New England Journal of Medicine
|
27 Nov 2024 |
285 |
| 8 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy
Graeme J Moyle, Caroline Anne Sabin, Jonathan Cartledge et al. · AIDS
|
18 Oct 2006 |
273 |
| 9 |
Severe events in donors after allogeneic hematopoietic stem cell donation
Jörg P. Halter, Yukihiro KODERA, Avaro Urbano Ispizua et al. · Haematologica
Open access |
5 Dec 2008 |
232 |
| 10 |
Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys
Daniel W. Drolet, J. Arly Nelson, Christopher E. Tucker et al. · Pharmaceutical Research
|
Dec 2000 |
206 |
| 11 |
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
Xiaoyan Chu, Mingxiang Liao, Hong Shen et al. · Clinical Pharmacology & Therapeutics
Open access |
22 Oct 2018 |
204 |
| 12 |
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Eric G. Meissner, David Wu, Anu O Osinusi et al. · Journal of Clinical Investigation
Open access |
Jul 2014 |
203 |
| 13 |
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Susan Olender et al. · Clinical Infectious Diseases
Open access |
22 Jul 2020 |
171 |
| 14 |
Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Patrick Marcellin, David Ka Ki Wong, William Sievert et al. · Liver International
Open access |
28 May 2019 |
164 |
| 15 |
A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
Manca Povsic, On Yee Wong, Richard A. Perry et al. · Advances in Therapy
Open access |
7 May 2019 |
157 |
| 16 |
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
Joseph J.�Y. Sung, Jak-Yiu Lai, Stefan Zeuzem et al. · Journal of Hepatology
|
3 Mar 2008 |
156 |
| 17 |
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus
M. Azim Ansari et al. · Nature Genetics
Open access |
10 Apr 2017 |
151 |
| 18 |
Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications
Mark A. Haverick, Selina Mengisen, Mohammed Shameem et al. · mAbs
Open access |
Apr 2014 |
138 |
| 19 |
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
J. Gerry Kenna, Kunal S. Taskar, Christina Battista et al. · Clinical Pharmacology & Therapeutics
Open access |
23 Aug 2018 |
119 |
| 20 |
Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma
Christine G. Kohn, Simon Blechman Zeichner, Qiushi Chen et al. · Journal of Clinical Oncology
Open access |
21 Feb 2017 |
109 |
| 21 |
Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3)
Xiaomin Liang, Huan‐Chieh Chien, Sook Wah Yee et al. · Molecular Pharmaceutics
Open access |
3 Nov 2015 |
109 |
| 22 |
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts
Alessandra Mangia et al. · Liver International
Open access |
25 May 2020 |
108 |
| 23 |
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Caron Alyce Jacobson, Javier L Munoz, Fang Sun et al. · Transplantation and Cellular Therapy
ReviewOpen access |
27 Oct 2023 |
106 |
| 24 |
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
Jason Grebely, Stefan Mauss, Ashley S Brown et al. · Clinical Infectious Diseases
Open access |
23 Aug 2016 |
101 |
| 25 |
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
Partow Kebriaei et al. · Transplantation and Cellular Therapy
Open access |
2 Dec 2017 |
98 |
| 26 |
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
K Walsh, T Woodall, P Lamy et al. · Gut
Open access |
Sep 2001 |
92 |
| 27 |
Opportunities and challenges in commercial pharmaceutical liposome applications
Gerard M. Jensen, Donald F. Hodgson · Advanced Drug Delivery Reviews
ReviewOpen access |
2020 |
84 |
| 28 |
Antiepileptic activity of preferential inhibitors of persistent sodium current
Lyndsey L. Anderson, Christopher H. Thompson, Nicole A. Hawkins et al. · Epilepsia
Open access |
23 May 2014 |
78 |
| 29 |
The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection
Kimberly L. Garrison, Polina German, Erik Mogalian et al. · Drug Metabolism and Disposition
Open access |
25 Apr 2018 |
71 |
| 30 |
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers
Sook Wah Yee, Marilyn M. Giacomini, Hong Shen et al. · Clinical and Translational Science
Open access |
13 Apr 2019 |
70 |
| 31 |
Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk Jacobus Blom, Michael J. Koren, Eli M. Roth et al. · Diabetes Obesity and Metabolism
|
13 Sep 2016 |
65 |
| 32 |
PhRMA White Paper on ADME Pharmacogenomics
J. Andrew Williams, Tommy Andersson, Tommy B. Andersson et al. · The Journal of Clinical Pharmacology
|
5 Jun 2008 |
65 |
| 33 |
Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A
Sarah Billington, Steven C. Shoner, Scott David Lee et al. · Clinical Pharmacology & Therapeutics
Open access |
18 May 2019 |
64 |
| 34 |
Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance
Maciej J. Zamek‐Gliszczynski, Vishal Sangha, Hong Shen et al. · Clinical Pharmacology & Therapeutics
|
13 May 2022 |
60 |
| 35 |
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
Oliver A. Cornely, Johan A. Maertens, Mark Bresnik et al. · Mycoses
Open access |
11 Oct 2010 |
58 |
| 36 |
Deranged sodium to sudden death
Colleen E. Clancy et al. · The Journal of Physiology
Open access |
13 Mar 2015 |
57 |
| 37 |
Intracellular Na+ overload causes oxidation of CaMKII and leads to Ca2+ mishandling in isolated ventricular myocytes
Serge Viatchenko‐Karpinski, Dmytro Kornyeyev, Nesrine El‐Bizri et al. · Journal of Molecular and Cellular Cardiology
Open access |
21 Sep 2014 |
57 |
| 38 |
Systematic review of the prevalence of psychiatric illness and sleep disturbance as co-morbidities of HIV infection in the UK
Mas Chaponda, Natalie V. J. Aldhouse, Michel Kroes et al. · International Journal of STD & AIDS
Review |
2 Feb 2018 |
56 |
| 39 |
Addressing HIV stigma in healthcare, community, and legislative settings in Central and Eastern Europe
Ana-Maria Schweitzer, Arian Dišković, Veronica Krongauz et al. · AIDS Research and Therapy
Open access |
11 Dec 2023 |
53 |
| 40 |
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions
Quentin Mark Anstee, Kate Hallsworth, Niall Lynch et al. · JHEP Reports
Open access |
22 Nov 2021 |
53 |
| 41 |
Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV : Real‐world insights from BICSTaR cohorts
Stefan Eßer, Jason M. Brunetta, Alexy Inciarte et al. · HIV Medicine
Open access |
26 Dec 2023 |
52 |
| 42 |
Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid Profiles
Georg M. N. Behrens, Renato Maserati, Armin Rieger et al. · Antiviral Therapy
|
Aug 2012 |
51 |
| 43 |
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina et al. · Infectious Diseases and Therapy
Open access |
9 Mar 2021 |
50 |
| 44 |
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children
Andrew D.J. Pearson et al. · European Journal of Cancer
|
14 Feb 2019 |
49 |
| 45 |
58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY
G.M. Dusheiko, Christophe Hézode, Stanislas Pol et al. · Journal of Hepatology
Open access |
2008 |
47 |
| 46 |
Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial Hypertension
Nicholas W. Morrell, Stephen L. Archer, Albert DeFelice et al. · Pulmonary Circulation
Open access |
2013 |
46 |
| 47 |
Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs)
Joel P. Bercu, Eric J. Morinello, Claudia Sehner et al. · Regulatory Toxicology and Pharmacology
|
25 May 2016 |
45 |
| 48 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz
Vanessa Cooper, Graeme J Moyle, Martin Fisher et al. · AIDS Care
|
5 Apr 2011 |
45 |
| 49 |
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom
Jack Williams, Peter T. Vickerman, Sam T Douthwaite et al. · Value in Health
Open access |
14 Jul 2020 |
40 |
| 50 |
Renal Transporter‐Mediated Drug‐Drug Interactions: Are They Clinically Relevant?
Eve‐Irene Lepist, Adrian S. Ray · The Journal of Clinical Pharmacology
Open access |
Jul 2016 |
40 |